Moderna said on Wednesday its experimental COVID-19 vaccine induced immune responses in older adults similar to those in younger participants, offering hope that it will be effective in people considered to be at high risk for severe complications from the coronavirus.
The analysis looked at subjects given the 100-microgram dose being tested in the much larger Phase III trial. Moderna said the immune responses in those aged between ages 56 and 70, above age 70 and those 18 to 55-years-old were similar.
The company has so far enrolled over 13,000 participants in its late-stage study. About 18% of the total participants are Black, Latino, Native American or Alaska Native, groups that have been particularly hard hit by the pandemic, and are often under represented in clinical trials.
BREAKING: Moderna says its coronavirus vaccine shows promising results in small trial of elderly patients https://t.co/yHMvkfZsBR
— CNBC Now (@CNBCnow) August 26, 2020
— Reuters (@Reuters) August 26, 2020